Palla Pharma (PAL.AX)

Overall impact
C (50)

Commentary

Palla Pharma is an average overall performer. With a 'C' rating of 50.1 for overall impact (42nd percentile compared to all companies), Palla Pharma ranks 223rd out of 255 industry peers, behind Catalyst Pharmaceuticals, Agios Pharmaceuticals, Pharmaron Beijing H and 219 others, and ahead of Teva, Collegium Pharmaceutical, Theratechnologies and 29 others. On top material causes for Palla Pharma's industry (Pharmaceuticals), Palla Pharma performs well in Child and Maternal Health (95.2 score), Child and Maternal Health (95.2), Access to Affordable Healthcare (85.9) and 12 other causes where it received an 'A' score and performs poorly in Disaster Readiness and Effective Aid (24.6 score), Decent, Safe Work Opportunities (25.6), Humane Treatment of Animals (0.0) and 24 other causes where it received a 'D' or 'F' score.
Screens
Impact
Cause PAL.AX
Peer rank
Overall impact

Log in to view this information

Screens
Impact trend

Change in rating for overall impact

Log in to view this information

Company
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Vic, Australia
Share classes
PAL.AX
Description
Palla Pharma Limited, a vertically integrated pharmaceutical company, produces and distributes narcotic raw materials, active pharmaceutical ingredients, and finished dosage formulations for pharmaceutical markets in Australia and Norway. It also produces and distributes poppy seeds to culinary markets. The company was formerly known as TPI Enterprises Limited and changed its name to Palla Pharma Limited in June 2019. Palla Pharma Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Material causes
Ethos considers the following causes material for Palla Pharma, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.